73.76USD-0.39%Mkt Cap: 6.40B USDP/E: —Last update: 2026-05-26
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humani…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap6.40B USD
Enterprise Value5.87B USD
Revenue (TTM)—
Gross Profit-190.44M USD
Net Income (TTM)-155.20M USD
Revenue/Share—
Last Price73.76 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees112
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-24.70
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B11.38
EPS (TTM)-2.12
EPS (Forward)-3.01
52W Range
13.9392% of range78.80
52W High78.80 USD
52W Low13.93 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.70%
ROA-19.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-169.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.18%
Net Debt-741.47M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio8.97
Quick Ratio8.80
Book Value/Sh6.532 USD
Cash/Share8.538 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateSep 8, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)95.20 USD
Target Range78.00 USD – 115.00 USD
# Analysts15
Ownership
Shares Out.86.84M
Float80.93M
Insiders5.90%
Institutions97.53%
Short Interest
Short Ratio8.9d
Short % Float15.07%
Short % Out.14.07%
Shares Short12.22M
Short (prev mo.)10.44M
Technical
SMA 5060.85 (+21.2%)
SMA 20035.16 (+109.8%)
Beta3.13
S&P 52W Chg28.31%
Avg Vol (30d)1.26M
Avg Vol (10d)1.14M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—